Abstract
Objective To review the evidence of effectiveness of dressings applied to venous leg ulcers.
Design Systematic review and meta-analysis.
Data sources Hand searches of journals and searches of electronic databases, conference proceedings, and bibliographies up to April 2006; contacts with dressing manufacturers for unpublished studies.
Studies reviewed All randomised controlled trials that evaluated dressings applied to venous leg ulcers were eligible for inclusion. Data from eligible studies were extracted and summarised independently by two reviewers using a data extraction sheet. Methodological quality was assessed independently by two reviewers.
Results The search strategy identified 254 studies; 42 of these fulfilled the inclusion criteria. Hydrocolloids were no more effective than simple low adherent dressings used beneath compression (eight trials; relative risk for healing with hydrocolloid 1.02, 95% confidence interval 0.83 to 1.28). For other comparisons, insufficient evidence was available to allow firm conclusions to be drawn. None of the dressing comparisons showed evidence that a particular class of dressing healed more ulcers. Some differences existed between dressings in terms of subjective outcome measures and ulcer healing rates. The results were not affected by the size or quality of trials or the unit of randomisation. Insufficient data were available to allow conclusions to be drawn about the relative cost effectiveness of different dressings.
Conclusions The type of dressing applied beneath compression was not shown to affect ulcer healing. The results of the meta-analysis showed that applying hydrocolloid dressings beneath compression produced no benefit in terms of ulcer healing compared with applying simple low adherent dressings. No conclusive recommendations can be made as to which type of dressing is most cost effective. Decisions on which dressing to apply should be based on the local costs of dressings and the preferences of the practitioner or patient.
Introduction
Multilayer compression bandaging has been identified as the gold standard in the treatment of venous leg ulcers.1 2 3 Dressings are usually placed over the ulcer before compression bandages or hosiery are applied, with the intention of promoting healing and preventing the bandages sticking to the wound. However, the evidence of any increased benefit provided by these dressings, which can contribute significantly to the cost of treating a venous leg ulcer, is less clear than for compression.
The range and type of dressings available have increased since the publication of a systematic review of dressings for venous ulcers by Bradley et al in 1999.4 Large numbers of different wound dressings are available, with many ways of classifying them—for example, by physical composition or by describing them as passive, active, or reactive. However, the evidence for their use is equivocal. Whether any particular dressing or type of dressing affects the healing of ulcers needs to be established. In addition, many of these dressings are relatively expensive, with a difference of up to six times in unit cost between the more expensive and cheaper dressings.5
This study was based on a recently published Cochrane Collaboration review.6 We aimed to assess the effectiveness of wound dressings used in the treatment of venous leg ulcers.
Methods
We sought to summarise all randomised controlled trials evaluating dressings in the treatment of venous leg ulcers. Two reviewers (SP and EAN) independently assessed trials for suitability; a third reviewer (JAM) arbitrated any disagreements. We excluded trials that included patients with wounds such as arterial and diabetic ulcers, unless the results for patients with venous ulcers were reported separately. We also excluded trials evaluating topical agents and skin grafting. To structure the many comparisons that can be made between dressings, and to avoid potential double counting of comparisons if we simply summarised the interventions by dressing types, we decided in advance to structure our comparisons as illustrated in box 1.
Box 1: Comparisons of dressing types
Hydrocolloids
Versus foam
Versus alginate
Versus hydrogel
Versus paste
Versus simple/non-adherent dressings
Versus other dressings
Versus other hydrocolloids
Foams
Versus simple/non-adherent dressings
Versus silicone dressings
Versus other foams
Alginate
Versus simple non-adherent dressings
Versus foam
Versus other alginates
Hydrogel
Versus simple/non-adherent dressings
Versus other hydrogel dressings
The primary outcome measure was time to complete ulcer healing or proportion of ulcers completely healed. We excluded composite outcome measures such as “number of ulcers healed or improved.”
We identified randomised controlled trials by searching Medline, Embase, and CINAHL, as well as the Cochrane Wounds Group specialised trials register up to April 2006. Box 2 shows details of all the databases searched and search terms used. We also sought grey literature by examining conference proceedings. We placed no restrictions in terms of language or year of publication. We also hand searched key journals, checked citations, and contacted experts in the field of wound care to enquire about ongoing and recently published trials.
Box 2: Details of search strategy
Search terms used in electronic searches
(Venous Ulcer or Foot Ulcer or Skin Ulcer or Leg Ulcer or Varicose Ulcer) and (Dressing* or Gauze* or Hydrocolloid* or Alginat* or Hydrogel* or Foam* or Film) and (Search filter for RCTs)
Conference proceedings examined
European Conference on Advances in Wound Management 1991-2003
European Tissue Repair Society (ETRS) Conference 1993-2001
American Symposia on Advanced Wound Care 1990-2001
Symposium on Venous Leg Ulcers 1985
British/Swedish Angiology Meeting 1991
Wound Healing and Scarring 1996
Meeting of the Venous Forum of the Royal Society of Medicine 1999
31st Annual Wound, Ostomy and Continence Nurses Conference 1999
Wound Healing Society Educational Symposium 2000
7th Annual Conference of the Canadian Association of Wound Care 2001
4th Australian Wound Management Association Conference 2002
Tissue Viability Society Conference 2003
Ostomy Wound Management 2003
Vascular Surgical Society of Great Britain and Ireland 2003
RCN International Nursing Research Conference 2004
2nd World Union of Wound Healing Societies' Meeting 2004
Wound Healing Society 16th Annual Meeting and Exhibition 2006
Journals hand searched
CARE—Science and Practice 1979-90
Decubitus 1987-93
Journal of the European Wound Management Association 2001-April 2006
Journal of Tissue Viability 1991-April 2006
Journal of Wound Care 1991-April 2006
Phlebology 1986-April 2006
Wound Repair and Regeneration 1993-April 2006
*Truncated
Two reviewers acting independently decided on the inclusion or exclusion of trials. A third reviewer (JAM) adjudicated on any disagreements about inclusion or exclusion. We considered trials for inclusion if they were randomised controlled trials evaluating dressings in the treatment of venous leg ulcers. Trials had to report time to complete ulcer healing, proportion of ulcers completely healed, or reduction in area (healing rate). We excluded composite outcome measures that aggregated, for example, healing and improvement. We assessed the quality of the trials on the basis of factors that have been shown to minimise bias and confounding.7 These were comparability of treatment groups at baseline; analysis of outcomes on an intention to treat basis, defined as all people who were allocated to a group being analysed in this intervention group regardless of the actual intervention used; completeness of follow-up; and the blinding and objectivity of outcome assessors.
We used Rev Man (4.1) to analyse data. All analysis was on an intention to treat basis, assuming withdrawals and losses to follow-up to be treatment failures. We estimated the relative risk of healing for each study; where similar interventions were compared in similar populations, we then considered using meta-analysis to estimate an aggregate relative risk. We assessed clinical heterogeneity by assessment of populations, concurrent treatment, trial setting, and outcome measures. Statistical heterogeneity was assessed by using the I2 test (we considered I2 values of 25% or less to indicate low heterogeneity and values of 75% or more to indicate high heterogeneity) and the χ2 test (we considered a significance level of P<0.1 to indicate heterogeneity8). In the absence of clinical and statistical heterogeneity, we used a fixed effect model. In the absence of clinical heterogeneity but the presence of statistical heterogeneity, we did a random effects meta-analysis. In the presence of clinical heterogeneity, we did a narrative review. A priori, we specified subgroup analyses to examine the robustness of the results on the basis of study size and the presence or absence of compression and allocation concealment.
Results
We contacted 14 authors about methods, outcomes, and type of wounds, of whom three replied. Figure 1 shows the stages of the process of meta-analysis using the QUOROM statement.9 Tables 1 to 3 show the characteristics of the included and excluded studies and the quality of the included studies.
Fig 1 Flow chart of identified trials. RCT=randomised controlled trial
Table 1.
Characteristics of included studies
| Reference | Participants | Dressing | Outcomes reported |
|---|---|---|---|
| Andersen 2002w3 | Netherlands and Denmark; n=118, but 99 included in analysis; duration 8 weeks | I1: FD (n=58; 53 included in analysis); I2: FD (n=60; 46 included in analysis) | No healed—I1: 18/53 (34%; ITT 18/58, 31%); I2: 18/46 (39%; ITT 18/60, 30%). Mean time to healing—I1: 5.2 (SD 1.9) weeks; I2: 5.0 (SD 1.7) weeks |
| Arnold 1994w15 | UK and USA; n=70; No of ulcers=90; duration 10 weeks | I1: HC (n=35); I2: standard dressing (n=35) | No healed—I1: 11/35 (31%); I2: 14/35 (40%). Mean reduction in ulcer area—I1: 71% (SE 4.3); I2: 43% (SE 7.1) |
| Backhouse 1987w16 | UK; n=56; duration 12 weeks | I1: HC (n=28); I2: LA (n=28) | No healed—I1: 21/28 (75%); I2: 22/28 (78%) |
| Banerjee 1997w31 | UK; n=71; duration 17 weeks | I1: FD (n=36); I2: LA (n=35) | No healed—I1: 11/36 (30.5%); I2: 8/35 (23.0%) |
| Banks 1996w20 | UK; n=100; duration 13 weeks | I1: HC (n=50); I2: FD (n=50) | No healed—I1: 19/50 (38%); I2: 18/50 (36%) |
| Blair 1988w4 | UK; n=120 “consecutive ulcers,” with 60 in each stage; duration 12 weeks | I1: HC; I2: Flamazine; control: LA | No healed—I1: HC 22/30 (73%), LA 23/30 (77%); I2: Flamazine 19/30 (63%), LA 24/30 (78%) |
| Bowszyc 1995w5 | Poland; n=80 (82 limbs); duration 12 weeks | I1: HC (n=40); I2: FD (n=40) | No healed—I1: 24/40 (60%); I2: 24/40 (60%) |
| Callam 1992w32 | UK; n=132 participants; duration 12 weeks | I1: FD (n=66); I2: LA (n=66) | No healed—I1: 31/66 (47%); I2: (23/66 (35%) (P=0.08) |
| Caprio 1994w29 | Italy; n=93 (98 ulcers); duration 8 weeks | I1: HC (n=49); I2: LCD (n=49) | No healed—I1: 25/49 (51%); I2: 20/49 (41%). Reduction in wound area (mm²/week)—I1: 152.7; I2: 103.66. Total mean cost (lira) dressing materials per patient (£=2400 lira)—I1: 102 607 (£42.75); I2: 142 527 (£59.37) |
| Charles 2002w19 | UK; n=91; duration 12 weeks | I1: FD (n=31); I2: HC (n=31); I3: HC (n=29) | No healed—I1: 18/31 (58%); I2: 17/31 (55%); I3: 17/29 (57%) |
| Eriksson 1984w38 | Sweden; n=53; part 2 excluded 9; duration 10 weeks | Part 1—I1: 0.9% normal saline; I2: HG; no detail of numbers provided for groups. Part 2—I1: porcine skin (n=11); I2: aluminium foil dressing (n=20); I3: zinc oxide and Tensoplast bandage (n=13) | Part 1—ulcer healing rate, states “no significant difference” between groups. Part 2—mean reduction in wound area, I1: 70%; I2: 10%; I3: 80% |
| Franks 2003w35 | UK; n=156; duration 24 weeks | I1: SD (n=75); I2: FD (n=81) | No healed—I1: 50/75 (66.7%); I2: 50/81 (61.7%) |
| Freak 1992w17 | UK; n=75; duration 6 weeks | I1: HC (n=25); I2: HC (n=25); I3: LA (n=25) | Reduction in mean ulcer area (cm²)—I1: 2.98 (SE 0.44); I2: 2.09 (SE 0.51); I3: 4.31 (SE 0.64); P>0.05. Median time to complete healing (life table)—I1: 6.85 weeks; I2: 4.25 weeks; I3: 6.17 weeks |
| Greguric 1994w30 | Croatia; n=110; duration “10 dressing changes” | I1: standard dressing (n=55); I2: HC (n=55) | No healed—I1: 0; I2: 3. Mean reduction in ulcer area (mm²/day)—I1: 21; I2: 32 |
| Groenwald 1984w6 | South Africa; n=72; duration 8 weeks | I1: conventional treatment (n=36); I2: HC (n=36) | Reduction in ulcer size—I1: 22.62%; I2: 67.64%; P<0.001 |
| Grotewohl 1994w27 | Germany; n=84, but only 63 participants reported; duration 28 days | I1: HG (n=39); I2: HC (n=24) | Reduction in ulcer area—I1: 44.6%; I2: 33.3%. Mean reduction in ulcer surface area—I1: 4.5 cm²; I2: 2.1 cm² |
| Hansson 1998w18 | Sweden/Denmark/Netherlands/UK; n=153; duration 12 weeks | I1: HG (n=56); I2: HC (n=48); I3: LA (n=49) | No healed—I1: 8/56 (14%); I2: 5/48 (10%); I3: 7/49 (14%) |
| Hornemann 1987w37 | Germany; n=148; duration 4 weeks | I1: HG (n=73); I2: HG (n=75) | Median wound reduction—I1: 50%; I2: 20% |
| Limova 1996w24 | USA; n=31; duration 8 weeks | I1: HC (n=17); I2: HC (n=14) | No healed—I1: 10/17 (60%); I2: 2/14 (14%) |
| Limova 2003w40 | USA; n=20, but only 19 included in analysis; duration 6 weeks | I1: AD (n=10); I2: AD (n=9) | No healed—I1: 0/10 (0%); I2: 2/9 (22%) |
| Lindholm 1994w28 | Sweden; n=28; duration 6 weeks | I1: GD (n=14); I2: HC (n=14) | Reduction in wound area—I1: 19%; I2: 51% |
| Meredith 1988w7 | UK; n=50, but one excluded from analysis; duration 6 weeks | I1: HC (n=25); I2: LA (n=24) | No healed—I1: 19/25 (76%); I2: 6/24 (25%). Total area healed (cm²)—I1: 21.1; I2: 7.7. Cost of dressing—I1: £436.86; I2; £855.87 |
| Moffatt 1992w39 | UK; n=60; duration 12 weeks | I1: AD (n=30); I2: LA (n=30) | No healed—I1: 26/30 (87%); I2: 24/30 (80%) |
| Moffatt 1992w9 | UK; n=60; duration 12 weeks | I1: HC (n=30); I2: LA (n=30) | No healed—I1: 13/30 (43%); I2: 7/30 (23%) |
| Mulder 1995w34 | UK; n=40 (39 reported); duration 16 weeks | I1: FD (n=19); I2: AD (n=20) | No healed—I1: 10/19 (53%); I2: 6/20 (30%) |
| Mulligan 1986w8 | UK; n=101 (97 reported); duration 6 weeks | I1: knitted fabric charcoal dressing (n=65); I2: conventional treatment decided by physician (n=35) | Mean ulcer reduction—I1: 28.7%; I2: 11.7%. Mean ulcer healing rate/week—I1: 1.2 cm; I2: 0.2 cm |
| Nelson 1995w10 | UK; n=200; duration 24 weeks | I1: LA (n=98); I2: HC (n=102) | No healed—I1: 44/98 (45%); I2: 49/102 (48%) |
| Ormiston 1985w11 | UK; n=61; duration 12 weeks | I1: HG and Melolin dressing (n=30; ITT=31); I2: standard treatment (gentian violet, Polyfax salmyxin, and bacitracin ointment plus gauze pad) (n=30) | No healed—I1: 12/31 (39%); I2: 7/30 (23%). Healing rate per week (cm²)—I1: 0.89 (SE 0.1); I2: 0.46 (SE 0.1); P=0.0001 |
| Pessenhoffer 1992w12 | Austria; n=48; duration 40 weeks | I1: FD (n=25); I2: LA (n=23) | Relative change in ulcer size—I1: decrease 65.6% (SD 47.0); I2: increase 78.3% (SD 215.8) |
| Scurr 1994w22 | UK; n=40; duration 6 weeks | I1: AD (n=20); I2: HC (n=20) | No healed—I1: 6/20 (30%); I2: 2/20 (10%)Mean reduction in area—I1: 90.7% (SD 14.5); I2: 80.2% (SD 22.4) |
| Skog 1983w42 | Sweden and Norway; n=95 (74 reported); duration 6 weeks | I1: HG (n=38); I2: standard treatment (n=36) | Mean reduction in ulcer area—I1: decrease of 34%; I2: increase of 5% |
| Smith 1994w23 | UK; n=40; duration 6 weeks | I1: HC (n=22); I2: AD (n=18) | No healed—I1: 4/22 (18%); I2: 2/18 (11%). Change in ulcer area—I1: 57.1%; I2: 34.9%. Cost of treatment—I1: £431.73; I2: £364.08 |
| Smith 1992w14 | UK; n=200; duration 16 weeks | I1: HC (n=99); I2: LA (n=101) | No healed—I1, small HC: 38/64 (56%); I2, small LA: 43/62 (69%); I1, large HC: 12/35 (34%); I2, large LA: 4/39 (10%). Cost of treatment—I1, small: £48.96; I2, small: £39.95; I1, large: £526.63; I2, large: £183.75 |
| Stacey 1997w41 | Australia; n=113, with 133 limbs; duration 36 weeks | I1: zinc oxide ointment impregnated woven cotton bandage (Viscopaste bandage); I2: zinc oxide ointment impregnated knitted stockinet (Acoband); I3: AD (Kaltostat) | No healed—I1: Viscopaste 34/43 (86%); I2: Acoband 26/44 (66%); I3: Kaltostat 26/46 (57%) |
| Taddeucci 2004w43 | Italy; n=17, with 24 ulcers; duration 8 weeks | I1: hyaluronan derivative fleece dressing (n=12 ulcers); I2: LA (n=12 ulcers) | No healed—I1: 2/12 (16%); I2: 1/12 (8%). Reduction in ulcer area (cm2)—I1: 8.1 (n=12); I2: 0.4 (P<0.002) |
| Tarvainen 1988w13 | Finland; n=27; duration 8 weeks | I1: HG (n=14); I2: HG (n=13) | No healed—I1: 7/14 (50%); I2: 5/13 (39%) |
| Veraart 1994w25 | Netherlands; n=38; duration 8 weeks | I1: HC (Comfeel extra-absorbing dressing) (n=19); I2: HC (Granuflex/Duoderm CGF) (n=19) | No healed—I1: 12/19 (63%); I2: 10/19 (53%) |
| Vin 2002w36 | France; n=73; duration 12 weeks | I1: HG (n=37); I2: LA (n=36) | No healed—I1: 18/37 (49%); I2: 12/36 (33%). Mean reduction in wound area—I1: 54.4% (SE 10); I2: 36.5% (SE 11.4). Median reduction in wound area—I1: 82.4%; I2: 44.6% |
| Vincentw26 | UK; n=29; duration 6 weeks | I1: HC (n=16); I2: HC (n=13) | Reduction in wound area—I1: 45%; I2: 57% |
| Weiss 1996w33 | USA; n=18; duration 16 weeks | I1: FD (n=10); I2: FD (n=8) | No healed—I1: 8/10 (80%); I2: 4/8 (50%). Mean time to healing—I1: 5.6 weeks; I2: 6.5 weeks |
| Wunderlich 1991w44 | Germany; n=40, of which 38 produced “evaluable” data; duration 6 weeks | I1: 5 days' cleaning with enzymatic debrider and then application of polyamide active charcoal dressing with 0.15% silver; I2: 5 days' cleaning using mechanical and enzymatic debridement and then dressing according to stage of healing. Granulation=paraffin oil or PVI (polyvinyl iodine) cream; epithelialisation=Fettgaze or oil in water emulsion | No healed—I1: 6/19 (31.6%, ITT=30%); I2: 2/20 (10.5%, ITT=10%). Reduction in wound area—I1: 60%; I2: 75% |
| Zuccarelli 1992w21 | France; n=40, but only 38 analysed; duration 12 weeks | I1: FD (n=19); I2: HC (n=19) | No healed—I1: 9/19 (47%); I2: 9/19 (47%) |
AD=alginate dressing; FD=foam dressing; HC=hydrocolloid; HG=hydrogel; GD=gauze dressing; I1=intervention 1; I2=intervention 2; I3=intervention 3; ITT=intention to treat; LA=low adherent; LCD=lyophilised collagen dressing; SD=silicone dressing.
Table 2.
Methodological quality of included studies
| Study | Baseline comparability | Inclusion and exclusion criteria | Method of randomisation | Allocation concealment | Sample size calculation | ITT | Blinding of outcome |
|---|---|---|---|---|---|---|---|
| Andersen 2002w3 | Yes | Yes | Yes | Adequate | No | No | Unclear |
| Arnold 1994w15 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Backhouse 1987w16 | Yes | No | No | Unclear | No | Yes | Unclear |
| Banerjee 1997w31 | No | Yes | No | Unclear | No | Yes | Unclear |
| Banks 1996w20 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Blair 1988w4 | Yes | Yes | Yes | Adequate | No | Yes | Unclear |
| Bowszyc 1995w5 | Yes | Yes | Yes | Unclear | No | No | Unclear |
| Callam 1992w32 | Yes | Yes | No | Adequate | No | Yes | Yes |
| Caprio 1994w29 | No | Yes | No | Unclear | No | Yes | Unclear |
| Charles 2002w19 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Eriksson 1984w38 | Yes | No | No | Unclear | No | No | Unclear |
| Franks 2003w35 | No | Yes | No | Unclear | No | Yes | Unclear |
| Freak 1992w17 | Yes | No | No | Unclear | No | Yes | Unclear |
| Greguric 1994w30 | Yes | No | No | Unclear | No | Yes | Unclear |
| Groenwald 1984w6 | No | No | Yes | Unclear | No | Yes | Unclear |
| Grotewohl 1994w27 | No | No | No | Unclear | No | No | Unclear |
| Hansson 1998w18 | No | Yes | No | Unclear | No | Yes | Unclear |
| Hornemann 1987w37 | No | No | No | Unclear | No | Yes | Unclear |
| Limova 1996w24 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Limova 2003w40 | No | No | No | Unclear | No | No | Unclear |
| Lindholm 1994w28 | No | Yes | No | Unclear | No | Yes | Unclear |
| Meredith 1988w7 | Yes | Yes | Yes | Unclear | No | No | Unclear |
| Moffatt 1992w39 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Moffatt 1992w9 | Yes | Yes | Yes | Unclear | Yes | Yes | Unclear |
| Mulder 1995w34 | No | No | No | Unclear | No | No | Unclear |
| Mulligan 1986w8 | Yes | Yes | Yes | Unclear | No | No | Unclear |
| Nelson 1995w10 | Yes | Yes | Yes | Adequate | Yes | Yes | Unclear |
| Ormiston 1985w11 | Yes | No | Yes | Adequate | No | No | Unclear |
| Pessenhoffer 1992w12 | No | No | Yes | Unclear | No | Yes | Unclear |
| Scurr 1994w22 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Skog 1983w42 | Yes | No | No | Unclear | No | No | Unclear |
| Smith 1994w23 | Yes | No | No | Unclear | No | Yes | Unclear |
| Smith 1992w14 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Stacey 1997w41 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Taddeucci 2004w43 | No | No | No | Unclear | No | Yes | Unclear |
| Tarvainen 1988w13 | Yes | Yes | Yes | Adequate | No | Yes | Unclear |
| Veraart 1994w25 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Vin 2002w36 | Yes | Yes | No | Unclear | No | Yes | Unclear |
| Vincentw26 | Yes | No | No | Unclear | No | Yes | Unclear |
| Weiss 1996w33 | No | No | No | Unclear | No | Yes | Unclear |
| Wunderlich 1991w44 | Yes | Yes | No | Unclear | No | No | Unclear |
| Zuccarelli 1992w21 | Yes | Yes | No | Unclear | No | No | Unclear |
ITT=intention to treat.
Table 3.
Reasons for exclusion of studies
| Study | Reason for exclusion |
|---|---|
| Agren 1990w45 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Alcaraz 2003w46 | Non-randomised study |
| Alicandro 2003w47 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Armstrong 1995w48 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Armstrong 1997w49 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Bale 1994w50 | Includes arterial ulcers, with no separate reporting by ulcer type |
| Bale 1998w51 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Ballard 2002w52 | Non-randomised study |
| Banks 1995w53 | No reporting of ulcer healing |
| Banks 1997w54 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Barnett 1988w55 | Review paper |
| Bartoletti 1997w56 | No reporting of ulcer healing |
| Berry 1993w57 | Evaluation of dressings for pilonidal sinus |
| Bianchi 2001w58 | Review article and case study |
| Bonnetblanc 2004w59 | Evaluation of protective spray not dressing |
| Brandrup 1990w60 | Includes arterial ulcers with no separate reporting by ulcer type |
| Brown-Etris 2004w61 | No reporting of ulcer healing |
| Bull 1995w62 | No reporting of ulcer healing |
| Burgess 1993w63 | No reporting of ulcer healing |
| Burgos 1989w64 | Evaluation of topical growth factors applied via dressings |
| Capillas 2000w65 | Reports cost to heal 1 cm2 ulcer; authors unable to provide more data |
| Casoni 2002w66 | Evaluation of compression |
| Chaloner 1992w67 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Chaloner 1996w68 | Did not report healing outcomes |
| Charles 2004w69 | Non-randomised study |
| Cherry 1996w70 | Study examining topical application |
| Cherry 2001w71 | Evaluation of topical application |
| Colletta 2003w72 | Non-randomised study |
| Collier 1992w73 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Cordts 1992w74 | Evaluates compression |
| Creese 1986w75 | Non-randomised study |
| Daniels 2002w76 | Non-randomised study |
| Davis 1992w77 | Evaluates compression |
| Diem 1987w78 | Non-randomised study |
| Dmochowska 1999w79 | No reporting of total number of ulcers healed or ulcer healing rates |
| Egan 1983w80 | Intervention is preparation for skin grafting; does not report healing |
| Eriksson 1986w81 | Evaluates double layer bandage system |
| Falanga 1998w82 | Evaluates skin graft |
| Farina 1997w83 | Does not report ulcer healing |
| Fivenson 2003w84 | Non-randomised study |
| Floden 1978w85 | Does not report ulcer healing |
| Frank 1979w86 | Does not report ulcer healing |
| Franken 1999w87 | Description of trial methods; no results |
| Franks 1993w88 | Letter; does not report outcome data |
| Friedman 1984w89 | Non-randomised study |
| Gamborg-Nielson 1989w90 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Gibson 1985w91 | Arterial ulcers only |
| Goldman 2003w92 | Non-randomised study |
| Halbert 1992w93 | Non-randomised study |
| Handfield-Jones 1988w94 | Crossover study with no report of ulcer healing at crossover point |
| Harcup 1986w95 | No breakdown of numbers randomised to each group |
| Hart 1998w96 | No breakdown of numbers allocated to groups; no reply to query |
| Hermans 2000w97 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Hoffman 2000w98 | Non-randomised study |
| Holloway 1989w99 | No data on ulcer healing |
| Hutchinson 1992w100 | Outcome measure “healed or improved;” no reply from author |
| Jasiel 1996w101 | Study examining absorbency of two dressings |
| Johnson 1992w102 | Study of dressings for pressure sores |
| Jones 2003w103 | No report of healing rates or total number of ulcers healed |
| Kalis 1993w104 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Kammerlander 2000w105 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Karlsmark 2003w106 | Non-randomised study |
| Kero 1987w107 | Non-randomised study |
| Kerstein 2000w108 | Non-randomised study |
| Kikta 1988w109 | Evaluation of compression |
| Koksal 2003w110 | Evaluation of compression |
| Kucharzewski 2003w111 | Evaluation of topical treatments |
| Lansdown 2003w112 | Non-randomised study |
| Larsen 1995w113 | No reporting of ulcer healing |
| Larsen 1997w114 | No reporting of ulcer healing |
| Larsen 2001w115 | No reporting of ulcer healing |
| Laudanska 1988w116 | Study endpoint combined complete healing and “very superficial” |
| Leaper 1991w117 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Lindholm 1993w118 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Lindholm 1995w119 | No reporting of ulcer healing |
| Ljunberg 1998w120 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Llewellyn 1995w121 | Non-randomised study |
| Loiterman 1991w122 | Non-randomised study |
| Margolis 1993w123 | Non-randomised study |
| Mayrovitz 1992w124 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| McMullen 1991w125 | Non-randomised study |
| Meaume 2002w126 | Non-randomised study |
| Meaume 2004w127 | No reporting of ulcer healing |
| Mekkes 1992w128 | No reporting of ulcer healing |
| Mian 1992w129 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Milward 1991w130 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Moody 2003w131 | No reporting of ulcer healing |
| Mulder 1993w132 | No reporting of ulcer healing |
| Mulder 1994w133 | States “statistically significant” differences but no results reported |
| Nowak 1995w134 | No reporting of ulcer healing |
| Nyfors 1982w135 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Ohlsson 1994w136 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Palmeri 1992w137 | Comparing topical agents |
| Perez 2000w138 | No reporting of ulcer healing |
| Petres 1993w139 | No reporting of ulcer healing |
| Polignano 2002w140 | No reporting of ulcer healing |
| Poole 1994w141 | No reporting of ulcer healing |
| Poskitt 1987w142 | Study of skin grafts. |
| Price 2003w143 | Non-randomised study |
| Price 2004w144 | No reporting of ulcer healing |
| Rainey 1993w145 | No reporting of ulcer healing |
| Reynolds 2004w146 | Reports “ulcer improved or healed” |
| Robinson 1993w147 | No reporting of ulcer healing |
| Robinson 1995w148 | Non-randomised study |
| Robinson 1996w149 | Report of trial design |
| Robinson 1997w150 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Robledillo 2002w151 | Non-randomised study |
| Rubin 1990w152 | Evaluation of compression |
| Rundle 1981w153 | No reporting of ulcer healing |
| Russell 2004w154 | Reports only composite outcome of “ulcer healed or improved” |
| Samson 1992w155 | No reporting of ulcer healing; no reply to query |
| Samson 1993w156 | Non-randomised study |
| Sayag 1996w157 | Trial of treatments for pressure ulcers |
| Scalise 2003w158 | Report of trial design |
| Schmutz 1996w159 | Report of trial design |
| Schulze 2001w160 | No reporting of ulcer healing |
| Scurr 1993w161 | Non-randomised study |
| Serafica 2003w162 | Non-randomised study |
| Sibbald 2004w163 | No reporting of ulcer healing |
| Sikes 1985w164 | Evaluation of compression |
| Sironi 1993w165 | No reporting of ulcer healing |
| Sironi 2003w166 | No reporting of ulcer healing |
| Skene 1992w167 | Reports development of prognostic index to predict time to healing |
| Slezak 2004w168 | Non-randomised study |
| Smith 1993w169 | Duplicate publication of Smith 1994w23 |
| Smith 2003w170 | Non-randomised study |
| Stewart 1987w171 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Strömberg 1984w172 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Teepe 1993w173 | Study examining skin grafts |
| Thomas 1988w174 | Review article |
| Thomas 1989w175 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Thomas 1997w176 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Torres 2003w177 | Non-randomised study |
| Tosti 1983w178 | Unclear if a randomised controlled trial; no reply to query |
| Varghese 1986w179 | Non-randomised study |
| Viamontes 2003w180 | Non-randomised study |
| Vin 1997w181 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Warburg 1994w182 | Study of skin grafting |
| Watts 1988w183 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Watts 1993w184 | Study of pressure ulcers and cavity wounds |
| Wayman 2000w185 | No reporting of ulcer healing |
| Westerhof 1990w186 | No reporting of ulcer healing |
| Westerhoff 1993w187 | No reporting of ulcer healing |
| Westerhoff 1995w188 | Report of imaging technique |
| Westh 1998w189 | No reporting of ulcer healing |
| Williams 1981w190 | Study of pilonidal sinus |
| Winter 1990aw191 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Winter 1990bw192 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Wollina 1997w193 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Worsley 1991w194 | Includes ulcers of mixed aetiology; no reporting by ulcer type |
| Zeegelaar 1994w195 | No reporting of ulcer healing |
| Zeegelaar 2001w196 | Non-randomised study |
Of 254 citations initially identified, 44 studies were eligible for inclusion. Two of these trials were ongoing (the VULCAN trial and the HALT trial).w1 w2 We therefore included 42 trials (59 citations) involving 3001 participants. Some trials used the limb or ulcer as the unit of randomisation; 3037 ulcers or limbs were included in the trials. Most (31/42, 74%) of the trials had 100 or fewer participants, and 36% (15/42) had fewer than 50 participants.
Table 2 shows details of the methodological quality of the trials. Trials that we deemed to be of high quality gave clear inclusion/exclusion criteria, described the method of randomisation and blinding of treatment allocation, analysed on an intention to treat basis, had comparable treatment groups at the start of the trial, and used valid outcome measures.
No inclusion criteria were reported for 38% of studies. Only 11 (26%) trials stated the method of randomisation.w3-w13 The others merely stated that treatment allocation was “randomised.” Most trials reported that the treatment groups were comparable at baseline. Most of the trials (31/42, 74%) reported the total number of ulcers healed during the trial. The remaining 26% (11/43) of trials used only the ulcer healing rate as an outcome measure. The duration of the trials ranged from four weeks to 48 weeks. The mean duration/follow-up was 14 weeks, and the median duration was eight weeks.
We used a random effects model to obtain aggregate outcomes for the relative risk of complete ulcer healing. This method allows for potential heterogeneity of the treatment effect between studies included in the meta-analysis. However, the conclusions from the analysis were the same with both fixed effects and random effects models, even allowing for the variations in precision between the two methods. The scope for subgroup analysis was limited owing to the small number of trials within each comparison. Table 4 shows the results of the meta-analysis.
Table 4.
Meta-analysis results
| Comparison | No of trials (total No of participants) | Pooled relative risk (95% CI) |
|---|---|---|
| Hydrocolloid v low adherent | 8 (792) (1 trial excludedw17) | 1.02 (0.83 to 1.25) |
| Hydrocolloid v foam | 4 (311) | 0.98 (0.79 to 1.22) |
| Hydrocolloid v alginate | 3 (80) | 0.72 (0.15 to 3.42) |
| Hydrocolloid v hydrocolloid | 3 (98) | 1.56 (0.67 to 3.63) |
| Foam v low adherent | 2 (203) (1 trial excludedw12) | 1.35 (0.93 to 1.94) |
| Foam v foam | 2 (136) | 1.2 (0.77 to 1.87) |
| Hydrogel v low adherent | 2 (151) | 1.53 (0.96 to 2.42) |
| Hydrogel v hydrogel | 2 (175) | NA |
NA=not applicable.
Hydrocolloid dressings
Twenty seven trials evaluated hydrocolloid dressings.
Hydrocolloid versus low adherent dressings
Nine trials (928 participants) compared hydrocolloid and low adherent dressings.w4w7w9w10w14-w18 We excluded one trial from the meta-analysis, however, as it did not report the number of people whose ulcer had healed.w17 The remaining eight trials included 792 people, and the pooled relative risk for healing with hydrocolloid was 1.02 (95% confidence interval 0.83 to 1.25) (fig 2).
Fig 2 Hydrocolloid dressings versus low adherent dressings
We detected significant heterogeneity within this comparison (I2=46.6%; χ2=13.11, df=7; P=0.07). Retrospective exploration of the heterogeneity identified one trial that seemed to differ from the others.w7 It included only small ulcers (wound area less than 5 cm2). Exclusion of this trial removed the statistical heterogeneity and did not affect the finding of no evidence of a difference in healing rate between hydrocolloids and simple low adherent dressings (relative risk=0.98, 0.85 to 1.12; I2=0%).
Hydrocolloid versus foam dressings
Four trials (311 participants) reported the total number of ulcers healed at 12 weeks for hydrocolloid dressings compared with foam dressings.w5w19-w21 Meta-analysis showed a pooled relative risk for healing of 0.98 (0.79 to 1.22) (fig 3), indicating no evidence of a statistically significant difference in healing rates. We detected no heterogeneity within the comparison (I2=0%; χ2=0.07, df=3, P=0.97). One of the trials used the ulcer rather than the patient as the unit of randomisation for the intervention.w5 Excluding this trial from the analysis did not affect the conclusions of the meta-analysis (relative risk=0.97, 0.74 to 1.28).
Fig 3 Hydrocolloid dressings versus foam dressings
Hydrocolloid versus alginate dressings
Two trials (80 participants) compared hydrocolloid dressings with alginate dressings.w22w23 The pooled relative risk for ulcer healing for hydrocolloids compared with alginate dressings was 0.72 (0.48 to 1.69) at 6-13 weeks. We found high heterogeneity (I2=52%; χ2=2.08, df=1; P=0.15).
One trial reported cost data and concluded that the cost of materials for hydrocolloids was £67 cheaper than for alginates.w23 However, no detail was given of how the costs were calculated, where the data included in the costs came from (from patients or from drug tariff data), or the type and extent of discounting used.
Hydrocolloid versus hydrocolloid
Three trials (98 participants) compared various hydrocolloid dressings.w24-w26 We could include only two in the meta-analysis, as one did not report the total number of ulcers healed.w26 The meta-analysis showed high heterogeneity (I2=69.7%; χ2=3.3, df=1; P=0.07) and no statistical difference between the dressings (relative risk=1.56, 0.67 to 3.63).
Hydrocolloid versus other dressings
Two trials (237 participants) compared hydrocolloid and hydrogel dressings.w18w27 One trial allocated treatment “according to the principle of random selection.”w27 The analysis was not intention to treat. The outcomes reported were percentage reduction in ulcer area at 28 days (44.6% hydrogel v 33.3% hydrocolloid) and the reduction of the ulcer surface area at 28 days (4.5 cm2 hydrogel v 2.1 cm2 hydrocolloid). The total number of ulcers healed in each group was not reported. The other trial had three arms and was also included in the hydrocolloid versus low adherent dressings comparison.w18
One trial (28 participants) compared hydrocolloid and gauze.w28 It reported a relative reduction in ulcer area of 19% for the gauze group and 51% for the hydrocolloid group. No statistical analysis of the results was reported.
One trial (93 participants with 98 ulcers) compared hydrocolloid dressing (Duoderm E) and a lyophilised collagen dressing.w29 The unit of randomisation was the ulcer and not the patient. No statistical differences between the dressings were reported.
One trial (110 participants) compared hydrocolloid dressing (Varihesive E) and magnesium sulphate paste beneath a gauze dressing.w30 The duration of the trial was for 10 dressing changes, but no details were given on trial length. The trial reported three ulcers healed in the hydrocolloid group and no ulcers healed in the other group.
Foam dressings
Foam versus low adherent dressings
Three trials (253 participants) compared foam dressings with low adherent dressings.w12w31w32 One trial did not report the total number of ulcers healed and so could not be included in the meta-analysis.w12 For the other two studies, the pooled relative risk was 1.35 (0.93 to 1.94), with no statistical heterogeneity (I2=0%; χ2=0.0, df=1; P=0.99).
Foam versus foam dressings
Two trials (136 participants) compared various foam dressings.w3w33 The aggregate relative risk of healing for the two studies was 1.2 (0.77 to 1.87), with no statistical heterogeneity (I2=0%, χ2=0.88, df=1; P=0.35).
Foam versus alginate dressings
One trial (40 participants) compared foam dressings with alginate dressings.w34 No statistically significant difference was found between the dressings. The reported hazard ratio for healing was 1.75 (0.79 to 3.88).
Foam versus silicone dressings
One trial (156 participants) compared foam dressings against silicone dressings.w35 No statistically significant difference was found between the dressings. The reported hazard ratio for healing was 1.17 (0.79 to 1.72).
Hydrogel dressings
Hydrogel versus low adherent dressings
Two trials (151 participants) compared hydrogel dressings with low adherent dressings.w11w36 The aggregate relative risk for healing with hydrogel compared with low adherent dressings was 1.53 (0.96 to 2.42; I2=0%, χ2=0.07, df=1; P=0.79).
Hydrogel versus hydrogel
Two trials (175 participants) compared different hydrogels.w13w37 However, we were unable to do a meta-analysis as only one trial reported the total number of ulcers healed, and this found no statistically significant difference between the two groups.w13
Hydrogel versus miscellaneous dressings
One trial (53 participants) consisted of two parts.w38 Part 1 compared 0.9% normal saline with Debrisan paste. This phase lasted two weeks, and the authors reported relative change in wound area. Part 2 of the study compared porcine skin (Skin-tec, Astra-Syntex, Sweden), aluminium foil dressing (Metallina, Lohmann GmbH, Germany), and a non-compressive double layer paste bandage. The authors gave no data on the total number of ulcers healed; they reported mean relative reduction in wound area.
Alginate dressings
Alginate versus low adherent dressings
One trial (60 participants) compared alginate with low adherent dressings.w39 It found no statistically significant difference between the two dressings (26/30 healing in the alginate group compared with 24/30 in the low adherent group; relative risk=1.08, 0.86 to 1.36).
Alginate versus alginate
One trial (20 participants) compared different alginate dressings (Tegagen HG and Sorbsan).w40 The study reported the total number of ulcers healed at eight weeks and found no statistically significant differences between the two groups (relative risk for healing with Tegagen=0.1, 0.01 to 1.86).
Three trials compared alginates with hydrocolloids,w20w22w23 and one trial compared alginate with a foam dressing.w34 These are summarised in the hydrocolloid and foam sections.
One trial (113 patients with 133 ulcerated limbs) compared alginate dressings in a three treatment arm trial.w41 The allocation was on the basis of the limb and not the patient. The treatments were zinc oxide impregnated cotton bandage (Viscopaste, n=43), zinc oxide impregnated stockinet (Acoband, n=44), and alginate dressing (Kaltostat, n=46). The study reported the total number of limbs healed. These were 34/43 (86%) in the Viscopaste arm, 26/44 (66%) in the Acoband arm, and 26/46 (57%) in the alginate arm. The relative risk of healing with the zinc paste bandage compared with the alginate dressing was 0.82 (0.61 to 1.1).
Miscellaneous dressings
One trial compared a cadoximer iodine powder and “standard” treatment as determined by the clinician.w42 The trial reported a mean percentage ulcer reduction of 34% in the cadoximer group compared with 5% in the standard group.
One trial compared a hyaluronan derivative fleece dressing with paraffin gauze dressing.w43 It found no statistically significant difference in the numbers of ulcers healed. Two (16%) of 12 ulcers healed in eight weeks in the fleece dressing group compared with 1/12 (8%) in the paraffin gauze group (χ2=0.39, df=1; P=0.53). It also reported a statistically significant reduction in ulcer area—8.1 cm2 for the fleece dressing compared with 0.4 cm2 for paraffin gauze (P<0.002).
One trial compared a polyamide active charcoal dressing with a dressing applied “according to the stage of healing.”w44 It found no statistically significant difference in the numbers healed at six weeks: 6/19 (31.5%) in the charcoal dressing group compared with 2/20 (10.5%) for the alternative (χ2=2.78, df=1; P=0.095).
Discussion
This review updates a systematic review published in 19994 and a more limited review published in 2005,10 which included only 16 studies, compared with 42 in our review. The results from our meta-analysis showed no statistically significant difference in terms of total ulcers healed between any of the dressing types. In some cases this may be due to low power to detect a difference. The meta-analysis of hydrocolloid dressings versus low adherent dressings had more than 700 participants. This means that we can be confident that hydrocolloids confer no significant clinical benefit over simple, low adherent dressings when used beneath compression. Given the potential disadvantages of using hydrocolloid rather than a low adherent simple dressing, in terms of increased cost and greater exposure to allergens in the preservative, the simple non-adherent dressing should be preferred.
One consideration when reviewing these results must be that an intention to treat perspective was used, which assumed that losses to follow-up failed to heal. This could have underestimated the healing rates.
Quality of included trials
Most of the trials included in this review had a small sample size (range 13-200, mean 76, median 70) and therefore had low power to detect clinically important differences. Only one study reported an a priori sample size calculation.w9 This was a concern, as small trials are at a higher risk of publication bias than large trials. Although the results for healing in these trials were usually inconclusive, and this might indicate that few trials in this area remain unpublished because of the direction of their findings, most trials were not inconclusive in their conclusions. They reported several outcome measures, usually subjective, such as dressing performance (ease of use, patient “comfort”), and often concluded that evidence existed for one dressing performing better than the other.
Most of the trials in this review were funded by dressing manufacturers, and we cannot be certain whether unpublished trials exist, or if, in the published trials, outcome measures have been selectively reported. Each comparison included too few trials to allow a funnel plot to be drawn.
We also found problems in terms of reporting of trials. Only three studies stated the method of randomisation and blinding of allocation,w4 w10 w11 and only one reported blinding of assessment.w19 Although blinding of trial participants to many wound dressings is difficult, as they often differ in appearance, blinding of the assessment of treatment can usually be achieved.
The lack of blinding of outcome assessors has implications in the light of a recent study that reported statistically significant differences in the subjective assessment of wound progress when the assessors were not blind to the dressing allocated, in contrast to an assessment by blinded outcome assessors in which no difference in wound progress was found.11 Evidence also exists to suggest that inadequate methodological reporting has an association with overestimation of treatment effects.12
The trials were of relatively short duration (range 4-48, mean 14, median 8 weeks). Venous ulcers usually take months to heal,13 so trials with short durations fail to capture most healing events, further eroding power to detect clinically important differences as statistically significant.
External validity of included trials
The external validity of many of these trials is threatened by the fact that they limited inclusion by ulcer size. Of the 23 studies that reported details of baseline ulcer area, 15 included only ulcers of less than 10 cm2 and eight included only ulcers of greater than 10 cm2. Only one trial used life table analysis, summarising both how many people's ulcers healed and how quickly they healed.w9 Many studies used rate of reduction in ulcer area as an outcome measure; however, this is not necessarily a predictor of healing, particularly when used over a short period. In addition, the use of change in wound area raises questions of validity, especially when initial ulcer size varies, as the percentage change will be greater for smaller wounds. The use of rates of reduction in area (often called ulcer healing rates) can therefore be misleading.14
Other outcome measures used included patient derived and nurse derived subjective measures such as “satisfaction” and pain. The use of subjective outcomes in trials can lead to bias, especially if the tools used are not tested for reliability and validity and if blinding to treatment allocation is not used. Bias can result from subconscious preferences of treatments by the assessors, patients, or both, or selective reporting of positive outcomes.
Cost and quality of life data
Cost and quality of life data used in the studies were also generally poor quality or lacking. When quality of life measures were reported they tended to be linear analogue scales or simple Likert-type scales. The inclusion of more sophisticated measures of quality of life when evaluating dressings is an area that needs to be tackled. This is particularly important as it may be one of the few ways to distinguish between dressings. The impact of venous ulcers on quality of life has been studied,15 16 17 18 19 20 but within randomised controlled trials quality of life data were very poor or omitted altogether.
The poor reporting of cost data was a particular concern. Where such data were collected,w7w14w29 the reporting did not conform to rigorous guidelines for economic evaluations.21 The trials simply totalled the monetary cost of the dressings and did not examine their cost effectiveness. This was illustrated in the hydrocolloid versus alginate comparison, where costs were reported for the interventions but insufficient detail was provided on their derivation.
Clinical implications
Although a wide variety of dressings are available, and used on venous leg ulcers, we found insufficient evidence to justify the use of a particular dressing or dressing type in preference to any other. In particular, the use of hydrocolloid dressings rather than simple, low adherent dressings should be questioned. In the absence of clear evidence of differences in clinical effectiveness, the optimum use of resources demands that the least expensive dressing should be used, although the preferences of patients and nurses may be important where little difference in cost exists. Cost effectiveness studies examining dressings for venous leg ulcers are urgently needed, as dressing frequency drives costs by influencing the amount of time taken by clinicians to treat ulcers.
What is already known on this topic
Dressings are applied over ulcers with a view to aiding healing and improving patients' comfort
A wide variety of brands and types of dressing are available, but the evidence for their effectiveness is equivocal
What this study adds
Insufficient evidence of effectiveness exists to recommend one type of dressing in preference to another
Hydrocolloid dressings offer no healing benefit compared with simple dressings under compression
In the absence of evidence for healing benefit, cost should be a factor in the choice of dressings
Supplementary Material
Contributors: SP and EAN reviewed articles and extracted and analysed the data. JAM reviewed articles and advised on inclusion. All authors contributed to drafting the article. SP is the guarantor.
Funding: NHS HTAP, Sheffield Teaching Hospitals Trust, University of York, University of Leeds. The opinions and conclusions expressed here are those of the authors and do not necessarily reflect those of the UK National Health Service or the Department of Health.
Competing interests: A trial by EAN was included in the review.
Ethical approval: Not needed.
Provenance and peer review: Non-commissioned; externally peer reviewed.
References
- 1.Cullum N, Nelson EA, Fletcher A, Sheldon T. Compression for venous leg ulcers. Cochrane Database Syst Rev 2001;(2):CD000265. [DOI] [PubMed]
- 2.Fletcher A, Cullum N, Sheldon TA. A systematic review of compression treatment for venous leg ulcers. BMJ 1997;315:576-80. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Palfreyman SJ, Lochiel R, Michaels JA. A systematic review of compression therapy for venous leg ulcers. Vasc Med 1998;3:301-13. [DOI] [PubMed] [Google Scholar]
- 4.Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D. Systematic reviews of wound care management: (2) dressings and topical agents used in the healing of chronic wounds. Health Technol Assess 1999;3(17 II):iii-126. [PubMed] [Google Scholar]
- 5.British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary London: BMA, RPS, 2007. (No 53.)
- 6.Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers. Cochrane Database Syst Rev 2006;(3):CD001103. [DOI] [PubMed]
- 7.NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews York: York Publishing Services, 2001. (CRD Report 4.)
- 8.Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. [DOI] [PubMed] [Google Scholar]
- 9.QUOROM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-900. [DOI] [PubMed] [Google Scholar]
- 10.Bouza C, Muñoz A, María J. Efficacy of modern dressings in the treatment of leg ulcers: a systematic review. Wound Repair Regen 2005;13:218-29. [DOI] [PubMed] [Google Scholar]
- 11.Reynolds T, Russell L, Deeth M, Jones H, Birchall L. A randomised controlled trial comparing Drawtex with standard dressings for exuding wounds. J Wound Care 2004;14:71. [DOI] [PubMed] [Google Scholar]
- 12.Schultz KJ. Subverting randomisation in controlled trials. JAMA 1995;274:1456-8. [PubMed] [Google Scholar]
- 13.Iglesias C, Nelson EA, Cullum NA, Torgerson DJ. VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers. Health Technol Assess 2004;8(29):iii. [DOI] [PubMed] [Google Scholar]
- 14.Ruckley CV. Evidence-based management of patients with leg ulcers. J Wound Care 1997;6:442-4. [DOI] [PubMed] [Google Scholar]
- 15.Lindholm C, Bjellerup M, Christensen OB, Zederfeldt B. Quality of life in chronic leg ulcer patients: an assessment according to the Nottingham Health Profile. Acta Derm Venereol 1993;73:440-3. [DOI] [PubMed] [Google Scholar]
- 16.Hamer C, Cullum NA, Roe BH. Patients' perceptions of chronic leg ulcers. J Wound Care 1994;3:99-101. [DOI] [PubMed] [Google Scholar]
- 17.Hareendran A, Bradbury A, Budd J, Geroulakos G, Hobbs R, Kenkre J, et al. Measuring the impact of venous leg ulcers on quality of life. J Wound Care 2005;14:53-7. [DOI] [PubMed] [Google Scholar]
- 18.Charles H. Living with a leg ulcer. J Community Nurs 1995;9(7):22-4. [Google Scholar]
- 19.Howard A, Davies AH. Health-related quality of life in patients with venous ulceration. Phlebology 2001;16:12-6. [Google Scholar]
- 20.Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol 1994;31:49-53. [DOI] [PubMed] [Google Scholar]
- 21.Drummond MF, Davies L. Economic analysis alongside clinical trials—revisiting the methodological issues. Int J Technol Assess Health Care 1991;7:561-73. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.